The potential of FMT as a therapy for Alzheimer’s disease is based on the concept that gut microbiota imbalances contribute to neuroinflammation and the progression of amyloid-β and tau pathologies, both of which are central to Alzheimer’s [174]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.